<div id="readability-page-1"><article>Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (&#34;Defence&#34; or the &#34;Company&#34;), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026.These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics. BIO-Europe Spring: Primary Focus on Strategic PartnershipsDefence will participate in BIO-Europe Spring (March 23-26, Lisbon, Portugal), the premier global partnering event for the life sciences industry. At BIO-Europe, the Company will prioritize discussions with biopharmaceutical partners seeking to collaborate on enhancing the intracellular delivery and efficacy of their ADC programs using Accum®.DCAT Week: Advancing Biomanufacturing CapabilitiesDefence will also attend DCAT Week (March 23-26, New York), where the Company will focus on strengthening its manufacturing strategy. During DCAT, Defence plans to meet with contract research and manufacturing partners to advance the robust and high-quality biomanufacturing of Accum®, a key operational objective for the Company. Defence has recently become a member of the Drug, Chemical &amp; Associated Technologies Association (&#34;DCAT&#34;), reinforcing its commitment to ensuring the well-characterized, quality-controlled, and commercially ready production of Accum®.Expanding U.S. Presence and Investor EngagementIn parallel, Defence will participate in the South Florida Life Sciences Showcase (March 24, Miami) and FII PRIORITY Miami (March 25-27), supporting the Company's ongoing investor outreach and business development efforts in the United States. Defence has also recently joined BioFlorida, further strengthening its footprint within the Florida life sciences ecosystem.&#34;As we engage with partners and industry stakeholders across these key events, our priority is to build meaningful collaborations that support the continued growth and adoption of Accum®,&#34; said Sébastien Plouffe, CEO of Defence Therapeutics. &#34;By enabling more efficient intracellular delivery of complex biologics, Accum® has the potential to significantly enhance therapeutic performance and tolerability, positioning the platform as a game-changing solution in the ADC field.&#34;. To explore partnering opportunities or schedule a meeting, please contact Defence Therapeutics at info@defencetherapeutics.com.About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information: Defence Therapeutics Sebastien Plouffe CEO, Founder and Director P: (514) 947-2272 Splouffe@defencetherapeutics.com www.defencetherapeutics.comCautionary Statement Regarding &#34;Forward-Looking&#34; InformationThis release includes certain statements that may be deemed &#34;forward-looking statements&#34;. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects&#34;, &#34;plans&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;projects&#34;, &#34;potential&#34; and similar expressions, or that events or conditions &#34;will&#34;, &#34;would&#34;, &#34;may&#34;, &#34;could&#34; or &#34;should&#34; occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.<img id="corporateNewsLogo" src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/285690_a3c92e1684e79a2b_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/285690_a3c92e1684e79a2b_logo.jpg"/>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285690<img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/285690/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/285690/375"/></article></div>

LABU

ARKG

Defence Therapeutics Inc. will showcase its Accum® platform at major international events in March 2026, including BIO-Europe Spring and DCAT Week, focusing on strategic partnerships and biomanufacturing capabilities. The company aims to enhance the intracellular delivery of antibody-drug conjugates and other biologics. Additionally, Defence will engage with investors at the South Florida Life Sciences Showcase and FII PRIORITY Miami, reinforcing its presence in the U.S. market. CEO Sébastien Plouffe emphasized the importance of building collaborations to support the growth of Accum® in the therapeutic field.

StockTitan

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Proshares UltraShort Nasdaq Biotech

SPDR S&P Biotech

Ark Genomic Revolution ETF

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March | DTCFF Stock News